Fig. 3From: Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastasesSelected biomarkers at baseline, 2 weeks, 4 weeks, and 8 weeks after 177Lu-DOTA-IBA therapy (ALT Alanine aminotransferase, AST Aspartate aminotransferase, GFR Glomerular filtration rate)Back to article page